Stock listing

NASDAQ:CRSP CRISPR Therapeutics AG Stock

Home listing (NASDAQ) of CRISPR Therapeutics AG

Follow CRISPR Therapeutics AG into a list and get an email when it puts out news.

Share price · NASDAQ:CRSP

$39.10 USD -1.09 (-2.7%)

Close on Nov 20, 2026

Past year -20.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$38.18 – $40.17 USDNov 20, 2026
Volume
3.32M sharesNov 20, 2026
Market cap
$3.79B USDAt the close on Nov 20, 2026 · price × 97.00M shares outstanding
52-week range
$38.18 – $63.45 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$89.03M USDMedian day 1.39M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
CRISPR Therapeutics AG logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CRSP · Home$39.10 USD-1.09 (-2.7%)3,321,805$38.18$40.17$38.18$40.19Close on Nov 20, 2026
LSE:0VRQ$39.51 USD+0.42 (+1.1%)8,682$38.60$40.23$38.11$39.09Close on Nov 20, 2026
Frankfurt:1CG€35.11 EUR-1.38 (-3.8%)—€35.11€35.11€35.11€36.49Close on Nov 20, 2026
B3:C2RS3429.88 BRL0.00 (0.0%)329.8829.8829.8829.88Close on Nov 19, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CRSP · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$39.10-1.09-2.7%$38.18$40.17$38.183,321,805
$40.19+0.04+0.1%$40.25$42.66$40.113,972,990
$40.15-0.22-0.5%$40.19$41.17$39.804,108,033
$40.37-1.87-4.4%$41.49$42.19$39.832,388,717
$42.24-0.38-0.9%$42.50$42.79$41.791,872,766
$42.62-3.13-6.8%$45.00$45.09$42.382,480,919
$45.75+0.60+1.3%$45.98$46.31$44.502,674,156
$45.15-4.89-9.8%$49.02$49.29$44.994,008,996
$50.04-0.03-0.1%$50.57$51.52$48.711,058,136
$50.07+1.51+3.1%$48.98$50.27$48.411,232,139
$48.56-3.215-6.2%$51.01$51.21$47.762,142,260
$51.78+1.785+3.6%$51.48$52.50$50.191,389,488
$49.990.000.0%$50.26$51.86$49.621,287,859
$49.99-1.43-2.8%$51.90$52.12$49.701,015,297
$51.42-2.84-5.2%$53.27$54.10$50.601,166,454
$54.26+0.15+0.3%$54.30$55.82$53.301,290,824
$54.11+2.64+5.1%$50.48$54.17$50.101,125,973
$51.47+2.46+5.0%$49.03$51.54$48.751,157,933
$49.01-0.38-0.8%$49.36$50.11$48.651,065,670
$49.39-0.60-1.2%$49.31$49.68$48.021,925,646
$49.99-0.51-1.0%$50.14$51.05$49.36906,106
$50.50+0.62+1.2%$50.13$50.94$49.551,171,126
$49.88-0.16-0.3%$48.87$50.33$47.362,156,437
$50.04+0.79+1.6%$49.83$50.30$49.091,177,042
$49.25-2.27-4.4%$51.20$51.36$49.051,518,000
$51.52+1.30+2.6%$50.00$52.37$49.761,352,700
$50.22+0.12+0.2%$49.67$50.78$48.911,703,000
$50.10-1.45-2.8%$51.01$51.11$49.771,340,800
$51.55-1.84-3.4%$52.91$53.21$51.401,103,600
$53.39+2.95+5.8%$50.82$54.07$50.521,465,700
$50.44-1.91-3.6%$51.51$53.54$50.022,863,400
$52.35-1.65-3.1%$53.00$54.59$52.271,679,200
$54.00-3.34-5.8%$60.39$60.68$53.742,622,800
$57.34+1.91+3.4%$55.21$57.46$54.011,701,300
$55.43-0.010.0%$56.45$57.58$54.091,128,300
$55.44+0.12+0.2%$55.45$56.59$54.821,058,000
$55.32-0.68-1.2%$56.55$57.11$55.281,165,000
$56.00+1.91+3.5%$54.08$56.48$54.001,576,100
$54.09-0.14-0.3%$53.84$55.63$52.901,269,700
$54.23-1.47-2.6%$56.14$56.39$53.921,007,800
$55.70-0.06-0.1%$54.95$57.17$53.791,554,900
$55.76-3.27-5.5%$59.11$59.52$54.672,361,400
$59.03+0.70+1.2%$58.73$60.72$57.642,080,800
$58.33+1.77+3.1%$57.98$59.24$56.871,813,500
$56.56-0.765-1.3%$58.00$59.34$55.633,382,000
$57.33+5.115+9.8%$53.90$59.21$53.122,997,100
$52.21+0.38+0.7%$52.16$53.67$51.832,663,300
$51.83-1.13-2.1%$52.57$52.85$51.491,248,100
$52.96+1.24+2.4%$51.33$53.80$51.331,523,700
$51.72-0.54-1.0%$52.35$53.21$51.62856,100
$52.26-1.19-2.2%$52.50$52.63$51.721,261,400
$53.45-1.33-2.4%$54.60$54.90$53.311,183,400
$54.78-1.01-1.8%$54.45$55.10$52.781,385,500
$55.79-0.70-1.2%$56.06$57.21$55.35904,200
$56.49-0.43-0.8%$57.50$57.80$55.721,487,700
$56.92+0.10+0.2%$57.13$58.96$55.59910,700
$56.82-0.16-0.3%$56.22$57.13$55.43890,500
$56.98-0.74-1.3%$56.55$57.49$56.201,390,800
$57.72-1.65-2.8%$58.22$59.37$57.101,386,300
$59.37+0.14+0.2%$59.12$60.11$58.021,186,900
$59.23-1.67-2.7%$60.18$60.39$58.06953,400
$60.90+3.825+6.7%$57.93$61.55$57.512,080,800
$57.08-2.425-4.1%$58.75$58.96$56.621,118,600
$59.50+1.38+2.4%$59.72$62.54$58.892,450,600
$58.12-1.69-2.8%$58.73$60.90$56.942,910,400

Splits

1 split · NASDAQ:CRSP · every price before a split is adjusted for it

DayRatioWhat
10-for-3Split
Ticker
NASDAQ:CRSP
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All CRISPR Therapeutics AG news

CRISPR Therapeutics AG on 6ix

Sector
Health care
Industry
Biotechnology
News releases
24 in the last 12 months · 167 in all · newest Nov 10, 2026 · oldest 2019
Decks
27 decks · latest November 2026

Where CRISPR Therapeutics AG is listed

ListingExchangeCountryCurrency
NASDAQ:CRSP · Home listing · This pageNASDAQUnited StatesUSD
Tradegate:1CGTradegateGermanyEUR
gettex:1CGgettexGermanyEUR
LS Exchange:A2AT0ZLS ExchangeGermanyEUR
Lang & Schwarz:A2AT0ZLang & SchwarzGermanyEUR
BOATS:CRSPBOATSUnited StatesUSD
LSE:0VRQLSEUnited KingdomUSD
Frankfurt:1CGFrankfurtGermanyEUR
BMV:CRSPNBMVMexicoMXN
B3:C2RS34B3BrazilBRL
BX Swiss:1CGBX SwissSwitzerlandCHF
BIVA:CRSPNBIVAMexicoMXN
Hamburg:1CGHamburgGermanyEUR
Munich:1CGMunichGermanyEUR
Dusseldorf:1CGDusseldorfGermanyEUR
Stuttgart:1CGStuttgartGermanyEUR
SET:CRSP03SETThailandTHB
Hanover:1CGHanoverGermanyEUR
Xetra:1CGXetraGermanyEUR

Valuation

EV/sales 83.7× against a median of 53.7×: 3rd lowest of 5 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$2.11B USD
P/E
Loss
EV/sales
83.7×
EV/EBITDA
Negative EBITDA
Price/book
2.3×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.4×
Beta vs S&P 500
1.64

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
CRISPR Therapeutics AG · NASDAQ:CRSPUS$3.79BUS$2.11Bn/a83.7×n/a2.3×n/a0.4×1.64
Dizal (Jiangsu) Pharmaceutical Co. Ltd. Class A · SSE:688192US$3.90BUS$3.18B7.5×4.3×n/a5.2×69.3%0.1×n/a
Definium Therapeutics, Inc. · NASDAQ:DFTXUS$3.88BUS$2.87Bn/an/an/a4.0×n/a0.0×1.14
Tango Therapeutics, Inc. · NASDAQ:TNGXUS$3.68BUS$2.74Bn/an/an/a3.8×n/a0.0×1.41
Xenon Pharmaceuticals Inc. · NASDAQ:XENEUS$3.64BUS$2.70Bn/an/an/a3.2×n/a0.0×0.80
Relay Therapeutics, Inc. · NASDAQ:RLAYUS$3.56BUS$2.74Bn/a265×n/a4.3×n/a0.0×1.48
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A · SSE:688336US$3.56BUS$3.42B7.6×5.1×n/a2.7×69.9%0.0×n/a
Enliven Therapeutics, Inc. · NASDAQ:ELVNUS$3.42BUS$2.54Bn/an/an/a3.9×n/a0.0×0.89
Disc Medicine, Inc. · NASDAQ:IRONUS$3.42BUS$2.80Bn/an/an/a5.7×n/a0.1×0.94
Viridian Therapeutics, Inc. · NASDAQ:VRDNUS$3.40BUS$2.69Bn/a102×n/a5.9×n/a0.4×1.00
Parabilis Medicines, Inc. · NASDAQ:PBLSUS$3.39BUS$2.53Bn/an/an/a3.4×n/a0.0×n/a
Median of the othersUS$3.56BUS$2.74B7.6×53.7×4.0×69.6%0.0×1.00

Forecasts

9 strong buy · 4 buy · 10 hold · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.

Price target
85.42 USD · Analysts' mean
EPS, year to Dec 2026
-4.53 · 19 analysts
Revenue, year to Dec 2026
35.49M · 19 analysts

Team and board

Officers

OfficerRole
Samarth KulkarniChief Executive Officer and Chairman of the Board
James R. KasingerGeneral Counsel and Secretary
Megan Wherry MennerHead of Human Resources
Naimish PatelChief Medical Officer
Siva SakhamuriChief Technical Officer
Stephen KennedyHead of Technical Operations

Board

DirectorRole
Samarth KulkarniChief Executive Officer and Chairman of the Board

Events

QuarterResultsShare move
Q3 2026Nov 2, 2026 · After close0.0%
Q2 2026Aug 3, 2026 · After close+7.1%
Q1 2026May 4, 2026 · After close−2.2%
Q4 2025Feb 12, 2026 · After close+8.5%
Q3 2025Nov 10, 2025 · Before open−1.0%
Q2 2025Aug 4, 2025 · After close−6.7%
Q1 2025May 6, 2025 · After close+3.3%
Q4 2024Feb 11, 2025 · After close+9.3%
Q3 2024Nov 5, 2024 · Before open−0.5%
Q2 2024Aug 5, 2024 · After close−0.7%
All 20 quarters
QuarterResultsShare move
Q1 2024May 8, 2024 · After close+0.5%
Q4 2023Feb 21, 2024 · Before open+4.7%
Q3 2023Nov 6, 2023 · After close+13.6%
Q2 2023Aug 7, 2023 · After close+9.7%
Q1 2023May 8, 2023 · After close+13.3%
Q4 2022Feb 21, 2023 · After close+8.0%
Q3 2022Nov 1, 2022 · After close+5.1%
Q2 2022Aug 8, 2022 · Before open−0.0%
Q1 2022May 9, 2022 · After close+9.4%
Q4 2021Feb 15, 2022 · After close+1.6%

Open Events

Decks

DeckKindSlidesDate
Corporate Update (November 2026)Corporate update40 slidesNovember 2026
Q3 2026 Earnings PresentationEarnings43 slidesAug 3, 2026
Corporate Update (February 2026)Corporate update43 slidesFeb 12, 2026
Investor Presentation (2025)Investor deck38 slidesNov 18, 2025
Corporate Update (2025)Corporate update33 slidesAug 24, 2025
Investor Presentation (July 2025)Investor deck33 slidesJuly 2025
Corporate Update (2024)Corporate update26 slidesNov 17, 2024
Investor Presentation (August 2024)Investor deck28 slidesAugust 2024
Investor Presentation (May 2024)Investor deck26 slidesMay 2024
Investor Presentation (March 2024)Investor deck28 slidesMarch 2024
All 27 decks
DeckKindSlidesDate
Investor Presentation (January 2024)Investor deck32 slidesJanuary 2024
Investor Presentation (2023)Investor deck44 slidesDec 20, 2023
Investor Presentation (March 2023)Investor deck42 slidesMarch 2023
Investor Presentation (2023)Investor deck32 slides2023
Investor Presentation (2022)Investor deck42 slidesOct 6, 2022
Investor Day (June 2022)Investor day6 slidesJun 21, 2022
Technical Presentation (June 2022)Technical16 slidesJun 13, 2022
Investor Presentation (June 2022)Investor deck35 slidesJune 2022
Investor Presentation (2022)Investor deck42 slides2022
Technical Presentation (October 2021)Technical20 slidesOct 12, 2021
Investor Presentation (2021)Investor deck35 slides2021
62nd Annual American Society of Hematology Meeting (December 2020)Conference18 slidesDec 7, 2020
62nd Annual American Society of Hematology Meeting (December 2020)Conference18 slidesDec 6, 2020
Technical Presentation (October 2020)Technical22 slidesOct 21, 2020
25th Congress of the European Hematology Association (Virtual Edition) (June 2020)Conference21 slidesJun 12, 2020
Technical Presentation (November 2019)Technical13 slidesNov 19, 2019
GTC Bio Cell and Gene Therapy (September 2015)Conference20 slidesSep 9, 2015

Open Decks

IPO

Priced at US$14.00 a share on Oct 18, 2016.

Price
US$14.00 a share
Shares offered
4,000,000 common shares
Offering size
US$56 million
Underwriters' option
Up to 600,000 more shares
Underwriters
Citigroup, Piper Jaffray, Barclays, Guggenheim Securities · In the order on the cover
Shares delivered
On or about Oct 24, 2016

Steps

StepWhen
Draft sent to the SEC in confidenceMay 13, 2016
Filed publiclySep 9, 2016
Amended twiceNewest Oct 14, 2016
Shares registered with an exchangeOct 18, 2016
Declared effective by the SECOct 18, 2016
Final prospectus, with the priceOct 19, 2016

Open IPO · From the cover of the final prospectus (424B4) filed Oct 19, 2016

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue3.51M37.3M371.2M1.20M915.0M719.0K289.6M3.12M41.0M5.16M
Research and development284.8M310.2M387.3M461.6M340.6M221.4M179.4M113.8M69.8M42.2M
Operating income-664.6M-466.6M-222.5M-673.2M373.5M-354.4M46.7M-158.9M-64.6M-68.1M
Depreciation and amortization19.5M19.3M19.8M24.2M18.0M9.18M4.72M3.52M3.02M925.0K
EBITDA-645.1M-447.3M-202.7M-649.0M391.5M-345.3M51.5M-155.4M-61.6M-67.2M
Income before tax-578.0M-362.7M-150.7M-650.5M379.5M-348.1M67.3M-164.4M-66.6M-22.7M
Income tax3.63M3.59M2.89M-325.0K1.87M809.0K448.0K553.0K1.75M484.0K
Net income-581.6M-366.3M-153.6M-650.2M377.7M-348.9M66.9M-165.0M-68.4M-23.2M
Earnings per share, basic-6.47-4.34-1.94-8.364.97-5.291.23-3.44-1.71-1.89
Earnings per share, diluted-6.47-4.34-1.94-8.364.70-5.291.17-3.44-1.71-1.89

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents347.6M298.3M389.5M211.9M923.0M1.17B943.8M456.6M239.8M315.5M
Short-term investments1.63B1.61B1.30B1.60B1.46B521.7M0
Receivables025.0M200.0M0305.0K144.0K99.0K88.0K2.63M3.16M
Current assets1.99B1.94B1.91B1.85B2.42B1.72B987.5M466.4M248.4M320.2M
Property, plant and equipment115.9M134.1M151.9M163.6M137.6M42.2M31.3M18.5M18.9M21.0M
Total assets2.27B2.24B2.23B2.24B2.75B1.83B1.07B489.0M271.3M345.0M
Accounts payable11.1M14.7M38.1M27.4M14.8M9.09M5.94M5.07M1.64M4.57M
Current liabilities149.1M87.8M108.8M121.1M119.9M94.3M57.1M27.7M14.5M22.0M
Total debt0
Total liabilities343.4M310.0M346.8M367.6M352.4M163.7M127.3M96.8M83.5M112.1M
Shareholders' equity1.92B1.93B1.88B1.88B2.40B1.66B939.4M392.2M187.8M232.8M
Shares outstanding95.9M85.7M80.0M78.5M77.0M73.9M60.8M51.9M40.6M39.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-345.0M-142.8M-260.4M-495.7M539.0M-238.4M56.7M-96.2M-70.1M-52.9M
Capital spending-914.0K-1.90M-9.47M-37.2M-81.7M-18.4M-6.68M-2.77M-7.81M-3.02M
Free cash flow-345.9M-144.7M-269.8M-532.9M457.3M-256.7M50.0M-99.0M-77.9M-55.9M
Cash from investing-31.8M-280.5M374.6M-258.7M-1.04B-541.2M1.32M-2.77M-8.31M31.9M
Cash from financing426.0M332.0M62.7M38.6M250.9M1.02B431.0M315.9M2.61M183.2M
Share buybacks-57.0K
Change in cash49.3M-91.3M177.0M-715.9M-245.5M236.7M489.0M216.9M-75.8M162.0M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 19, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 10, 2026Big-stake noticeSEC
144 · Notice of proposed saleNov 6, 2026Other filingsSEC
4 · Change in ownershipNov 6, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 2, 2026Insider tradeSEC
10-Q · Quarterly reportNov 2, 2026Quarterly reportSEC
8-K · Current reportNov 2, 2026ResultsSEC
4 · Change in ownershipOct 28, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 28, 2026Insider tradeSEC
4 · Change in ownershipOct 28, 2026Insider tradeSEC
4 · Change in ownershipOct 28, 2026Insider tradeSEC
4 · Change in ownershipOct 21, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 21, 2026Insider tradeSEC
4 · Change in ownershipOct 20, 2026Insider tradeSEC
8-K · Current reportOct 19, 2026Management or board changeSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
4 · Change in ownershipOct 15, 2026Insider tradeSEC
4 · Change in ownershipOct 15, 2026Insider tradeSEC
144 · Notice of proposed saleOct 14, 2026Other filingsSEC
4 · Change in ownershipOct 8, 2026Insider tradeSEC
144 · Notice of proposed saleOct 6, 2026Other filingsSEC
4 · Change in ownershipSep 24, 2026Insider tradeSEC
144 · Notice of proposed saleSep 22, 2026Other filingsSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
144 · Notice of proposed saleSep 17, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
10-Q · Quarterly reportAug 3, 2026Quarterly reportSEC
8-K · Current reportAug 3, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 27, 2026Big-stake noticeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
S-8 · Registration statement for employee plansJun 5, 2026Offer documentSEC
8-K · Current reportJun 4, 2026Management or board changeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 4, 2026Quarterly reportSEC
8-K · Current reportMay 4, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 30, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 21, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 21, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 21, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 2, 2026Meeting noticeSEC
4 · Change in ownershipMar 24, 2026Insider tradeSEC
4 · Change in ownershipMar 24, 2026Insider tradeSEC
4 · Change in ownershipMar 24, 2026Insider tradeSEC
4 · Change in ownershipMar 24, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
8-K · Current reportMar 16, 2026Material contractSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
8-K · Current reportMar 11, 2026Current reportSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
10-K · Annual reportFeb 12, 2026Annual reportSEC
8-K · Current reportFeb 12, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2026Big-stake noticeSEC
4 · Change in ownershipJan 27, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
144 · Notice of proposed saleJan 22, 2026Other filingsSEC
144 · Notice of proposed saleJan 22, 2026Other filingsSEC
144 · Notice of proposed saleJan 20, 2026Other filingsSEC
8-K · Current reportJan 12, 2026Current reportSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 22, 2025Insider tradeSEC
144 · Notice of proposed saleDec 22, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 4, 2025Big-stake noticeSEC
4 · Change in ownershipOct 20, 2025Insider tradeSEC
4 · Change in ownershipOct 15, 2025Insider tradeSEC
4 · Change in ownershipOct 15, 2025Insider tradeSEC
8-K · Current reportOct 15, 2025Current reportSEC
424B5 · ProspectusOct 15, 2025Offer documentSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
4 · Change in ownershipSep 19, 2025Insider tradeSEC
4 · Change in ownershipAug 19, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
10-Q · Quarterly reportAug 4, 2025Quarterly reportSEC
8-K · Current reportAug 4, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 17, 2025Big-stake noticeSEC
4 · Change in ownershipJul 17, 2025Insider tradeSEC
8-K · Current reportJun 26, 2025Current reportSEC
3/A · Initial statement of ownership, amendedJun 10, 2025Insider tradeSEC
8-K · Current reportJun 9, 2025Meeting outcomeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
424B5 · ProspectusMay 19, 2025Offer documentSEC
8-K · Current reportMay 19, 2025Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 6, 2025Quarterly reportSEC
8-K · Current reportMay 6, 2025ResultsSEC
ARS · Annual report to shareholdersApr 16, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 16, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 16, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 3, 2025Meeting noticeSEC
8-K · Current reportMar 26, 2025Management or board changeSEC
4 · Change in ownershipMar 24, 2025Insider tradeSEC
4 · Change in ownershipMar 24, 2025Insider tradeSEC
4 · Change in ownershipMar 24, 2025Insider tradeSEC
4 · Change in ownershipMar 24, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 12, 2025Insider tradeSEC
4 · Change in ownershipMar 12, 2025Insider tradeSEC
4 · Change in ownershipMar 12, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
144 · Notice of proposed saleFeb 18, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
10-K · Annual reportFeb 11, 2025Annual reportSEC
8-K · Current reportFeb 11, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 10, 2025Big-stake noticeSEC
4 · Change in ownershipDec 27, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedDec 10, 2024Big-stake noticeSEC
4 · Change in ownershipDec 4, 2024Insider tradeSEC
4 · Change in ownershipNov 13, 2024Insider tradeSEC
144 · Notice of proposed saleNov 12, 2024Other filingsSEC
10-Q · Quarterly reportNov 5, 2024Quarterly reportSEC
8-K · Current reportNov 5, 2024ResultsSEC
4 · Change in ownershipOct 18, 2024Insider tradeSEC
4 · Change in ownershipOct 18, 2024Insider tradeSEC
4 · Change in ownershipOct 18, 2024Insider tradeSEC
4 · Change in ownershipOct 18, 2024Insider tradeSEC
4 · Change in ownershipOct 18, 2024Insider tradeSEC
4 · Change in ownershipOct 15, 2024Insider tradeSEC
4 · Change in ownershipOct 15, 2024Insider tradeSEC
4 · Change in ownershipAug 12, 2024Insider tradeSEC
S-3ASR · Registration statementAug 5, 2024Offer documentSEC
S-8 · Registration statement for employee plansAug 5, 2024Offer documentSEC
10-Q · Quarterly reportAug 5, 2024Quarterly reportSEC
8-K · Current reportAug 5, 2024ResultsSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
8-K · Current reportJun 3, 2024Management or board changeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 30, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 30, 2024Insider tradeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 28, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 23, 2024Insider tradeSEC
8-K · Current reportMay 23, 2024Management or board changeSEC
10-Q · Quarterly reportMay 8, 2024Quarterly reportSEC
8-K · Current reportMay 8, 2024ResultsSEC
4 · Change in ownershipApr 17, 2024Insider tradeSEC
144 · Notice of proposed saleApr 15, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedApr 10, 2024Big-stake noticeSEC

This page holds 200 of 886 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from CRISPR Therapeutics AG’s releases

Common shares
97,000,813
Fully diluted
97,000,813

Fully diluted

LineShares
Common shares97,000,813

Share count over time

CountShares
Nov 22, 202697,000,813

Open Cap table

Shareholders

Funds

HolderSharesValueAs of
ARK Innovation ETF5.49MUS$263MJul 31, 2026
iShares Russell 2000 ETF2.39MUS$131MJun 30, 2026
ARK Genomic Revolution ETF2.04MUS$97.9MJul 31, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF2.01MUS$110MJun 30, 2026
New Perspective Fund1.94MUS$106MJun 30, 2026
SMALLCAP World Fund Inc1.69MUS$92.4MJun 30, 2026
Growth Fund of America1.41MUS$79.4MMay 31, 2026
Vanguard Extended Market Index Fund1.11MUS$60.4MJun 30, 2026
T. Rowe Price Mid-Cap Growth Fund, Inc.1.05MUS$57.3MJun 30, 2026
Fidelity Small Cap Index Fund1.02MUS$48.9MJul 31, 2026
Show 50 holders
HolderSharesValueAs of
iShares Russell 2000 Value ETF760KUS$41.4MJun 30, 2026
iShares Biotechnology ETF635KUS$34.6MJun 30, 2026
Fidelity Growth Company Fund593KUS$33.3MMay 31, 2026
Fidelity Extended Market Index Fund497KUS$27.9MMay 31, 2026
Vanguard Russell 2000 Index Fund469KUS$26.4MMay 31, 2026
Schwab U.S. Small-Cap ETF462KUS$26MMay 31, 2026
Growth Fund335KUS$18.3MJun 30, 2026
Schwab U.S. Mid-Cap ETF260KUS$14.6MMay 31, 2026
Tax-Managed U.S. Mid & Small Cap Fund252KUS$12.1MJul 31, 2026
Schwab Small-Cap Index Fund226KUS$10.9MJul 31, 2026
Fidelity Total Market Index Fund180KUS$10.1MMay 31, 2026
Master Small Cap Index Series172KUS$9.38MJun 30, 2026
Fidelity Growth Company K6 Fund168KUS$9.43MMay 31, 2026
Fidelity Series Total Market Index Fund148KUS$8.3MMay 31, 2026
American Beacon ARK Transformational Innovation Fund143KUS$7.79MJun 30, 2026
iShares Core S&P Total U.S. Stock Market ETF128KUS$6.96MJun 30, 2026
Nuveen Small Cap Blend Index Fund122KUS$5.84MJul 31, 2026
T. Rowe Price Institutional Mid-Cap Equity Growth Fund119KUS$6.49MJun 30, 2026
Fidelity Small Cap Value Index Fund113KUS$6.17MJun 30, 2026
iShares Russell 2000 Growth ETF113KUS$6.15MJun 30, 2026
Fidelity Series Growth Company Fund105KUS$5.92MMay 31, 2026
Avantis U.S. Small Cap Equity ETF104KUS$5.84MMay 31, 2026
EQ/2000 Managed Volatility Portfolio101KUS$5.52MJun 30, 2026
Empower T. Rowe Price Mid Cap Growth Fund93,400US$5.09MJun 30, 2026
Fidelity Enhanced Small Cap Core ETF89,612US$4.89MJun 30, 2026
MassMutual Mid Cap Growth Fund86,906US$4.74MJun 30, 2026
Vanguard Total World Stock Index Fund75,392US$3.62MJul 31, 2026
JNL Multi-Manager Small Cap Value Fund72,157US$3.94MJun 30, 2026
Vanguard Russell 2000 Value Index Fund71,986US$4.04MMay 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares68,253US$3.28MJul 31, 2026
Nuveen Equity Index Fund67,196US$3.22MJul 31, 2026
LVIP State Street Small-Cap Index Fund64,200US$3.5MJun 30, 2026
iShares Genomics Immunology and Healthcare ETF62,247US$2.99MJul 31, 2026
Fidelity Nasdaq Composite Index Fund58,462US$3.28MMay 31, 2026
iShares U.S. Small-Cap Equity Factor ETF57,543US$2.76MJul 31, 2026
Schwab U.S. Broad Market ETF57,051US$3.21MMay 31, 2026
Schwab Total Stock Market Index Fund57,024US$2.74MJul 31, 2026
EQ/Small Company Index Portfolio55,270US$3.01MJun 30, 2026
Fidelity ZERO Total Market Index Fund52,225US$2.51MJul 31, 2026
T. Rowe Price Mid Cap Growth Portfolio51,292US$2.8MJun 30, 2026

This page holds 50 of 205 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Kulkarni Samarth
Director, Officer: Chief Executive Officer
Sale47,837USD 49.78US$2.38MOct 19, 2026
George Simeon
Director
Sale14,514USD 49.63US$720KOct 14, 2026
Kulkarni Samarth
Director, Officer: Chief Executive Officer
Sale4,098USD 49.26US$202KOct 14, 2026
Kasinger James R.
Officer: General Counsel and Secretary
Sale1,040USD 49.26US$51,230Oct 14, 2026
Kasinger James R.
Officer: General Counsel and Secretary
Sale1,990USD 60.04US$119KOct 6, 2026
Kasinger James R.
Officer: General Counsel and Secretary
Sale10,400USD 60.24US$626KSep 22, 2026
Behbahani Ali
Director
Sale13,679USD 57.09US$781KSep 17, 2026
Patel Naimish
Officer: Chief Medical Officer
Sale3,786USD 55.62US$211KMay 29, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Ali Behbahani
Other companies: SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); NeueHealth Inc (Director · Since at least Oct 2, 2025); Korro Bio, Inc. (Director · Since at least Nov 3, 2023); Arcellx Inc (Director · Since at least Feb 3, 2022); Monte Rosa Therapeutics, Inc. (Director · Since at least Jun 23, 2021); Nkarta, Inc. (Director · Since at least Jul 9, 2020); Black Diamond Therapeutics, Inc. (Director · Since at least Jan 29, 2020); Adaptimmune Therapeutics PLC (Director · Since at least Jul 2, 2019); Minerva Surgical, Inc. (Director · Oct 21, 2021 – Jun 10, 2022 · Past); CVRx, Inc. (Director · Jun 29, 2021 – Jun 4, 2024 · Past); Oyster Point Pharma Inc (Director · Oct 30, 2019 – Jan 3, 2023 · Past)
Director · Since at least Jun 11, 2019
Briggs Morrison
Other companies: Werewolf Therapeutics, Inc. (Director · Since at least Apr 29, 2021); Arvinas, Inc. (Chair of the Arvinas Board of Directors · Since at least Sep 26, 2018); Carisma Therapeutics, Inc. (Director · Mar 7, 2023 – Jun 26, 2024 · Past); Codiak BioSciences Inc (Director · Oct 13, 2020 – Feb 17, 2021 · Past); Oncorus Inc (Director · Oct 1, 2020 – Oct 1, 2020 · Past); Repare Therapeutics Inc (Director · Jun 18, 2020 – Jun 17, 2024 · Past); NextCure, Inc. (Director · May 8, 2019 – Jun 11, 2020 · Past); Syndax Pharmaceuticals, Inc. (Director · Mar 2, 2016 – Feb 7, 2024 · Past)
Director · Since at least Jun 5, 2025
John Greene
Other companies: Northrop Grumman Corporation (Corporate Vice President and Chief Financial Officer · Since at least Jan 7, 2026); Discover Financial Services (EVP, Chief Financial Officer · Sep 18, 2019 – May 18, 2025 · Past); Bioverativ Inc (EVP, CFO and Treasurer · Dec 22, 2016 – Mar 8, 2018 · Past); Willis Towers Watson Public Limited Company (Chief Financial Officer · Jun 2, 2014 – Nov 9, 2015 · Past)
Director · Since at least Jun 11, 2019
Samarth Kulkarni
Other companies: Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); Centessa Pharmaceuticals PLC (Director · Since at least May 27, 2021); Black Diamond Therapeutics, Inc. (CEO, CRISPR Therapeutics AG · Since at least Jan 29, 2020); Repare Therapeutics Inc (Director · Jun 18, 2020 – Jun 17, 2024 · Past)
Chief Executive Officer and Chairman of the Board · Since at least Oct 18, 2016
Simeon George
Other companies: ADARx Pharmaceuticals, Inc. (Director · Since at least Sep 24, 2026); Design Therapeutics, Inc. (Director · Since at least Jun 15, 2022); Nkarta, Inc. (Director · Since at least Apr 28, 2022); Turning Point Therapeutics Inc (Director · Aug 17, 2022 – Aug 17, 2022 · Past)
Director · Since at least Jun 9, 2022
Harold Edward Fleming
Other companies: Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Upstream Bio, Inc. (Director · Since at least Oct 10, 2024)
Director · Since at least Jun 10, 2021
Brendan Smith
Other companies: Translate Bio Inc (Chief Financial Officer · Apr 19, 2021 – Sep 14, 2021 · Past)
Chief Financial Officer · Oct 14, 2021 – Feb 18, 2023 · Past
Maria Fardis
Other companies: Obsidian Therapeutics, Inc. (Director · Since at least Aug 3, 2026)
Director · Since at least Jun 5, 2025
Naimish Patel
Other companies: AgomAb Therapeutics NV (Non-Executive Director · Since at least Sep 11, 2026)
Chief Medical Officer · Since at least Jun 1, 2026
Christian RommelDirector · Since at least May 30, 2024
All 17 people
PersonSeat
James R. KasingerGeneral Counsel and Secretary · Since at least Sep 10, 2019
Megan Wherry MennerHead of Human Resources · Since at least Nov 4, 2026
Raju PrasadChief Financial Officer · Since at least Mar 14, 2023
Rodger NovakPresident, Director · Jun 10, 2019 – Jun 30, 2021 · Past
Siva SakhamuriChief Technical Officer · Since at least Nov 2, 2026
Stephen KennedyHead of Technical Operations · Since at least Nov 4, 2026
Tyler Dylan-HydeChief Legal Officer · Oct 18, 2016 – Jan 16, 2018 · Past

Open People

Log in to ask 6ix AI your own questions about CRISPR Therapeutics AG.